CTOs on the Move

Family Care Center

www.fcsprings.com

 
Family Care Center provides counseling, medication management, and TMS. We specialize in mental health care for the entire family. Call today to learn more.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.fcsprings.com
  • 1330, Quail Lake Loop
    Colorado Springs, CO USA 80906
  • Phone: 719.540.2146

Executives

Name Title Contact Details

Similar Companies

Organon

At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women`s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to her, today and every day.

Clinigen Group

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Companys principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through ...

Engrail Therapeutics

Founded in 2019, Engrail is supported by a long-term capital commitment from Nan Fung Life Sciences (NFLS).

Elevation Spine

Elevation Spine is a medical device company with a proprietary technology platform, Saber Technology, which is an advanced and differentiated approach to spinal fusion. The fusion procedure is highly efficient while remaining minimally invasive.

Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.